This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceuticalcompanies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drugdevelopment , within the next 24-months.
In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceuticalcompanies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’
With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026.
When COVID hit, the urgent need to accelerate drugdevelopment meant shrinking timelines from years to months, with no room for compromises on quality. Cloud-based tools allowed pharma companies to capture and share clinical data between research teams both securely and quickly.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content